TESARO Inc. (TSRO) Drops 7.38% on January 07

Equities Staff |

TESARO Inc. (TSRO) was one of the Russell 2000's biggest losers for Thursday January 07 as the stock slid 7.38% to $41.48, a loss of $-3.305 per share. Starting at an opening price of $43.21 a share, the stock traded between $40.57 and $43.40 over the course of the trading day. Volume was 423,217 shares over 3,966 trades, against an average daily volume of 556,751 shares and a total float of 40.09 million.

The losses send TESARO Inc. down to a market cap of $1.66 billion. In the last year, TESARO Inc. has traded between $66.95 and $36.14, and its 50-day SMA is currently $49.33 and 200-day SMA is $53.27.

Tesaro Inc is an oncology-focused biopharmaceutical company engaged in improving the lives of cancer patients. The Company is developing three clinical-stage product candidates including rolapitant, niraparib and TSR-011.

TESARO Inc. is based out of Waltham, MA and has some 275 employees. Its CEO is Leon O. Moulder.

For a complete fundamental analysis analysis of TESARO Inc., check out Equities.com’s Stock Valuation Analysis report for TSRO. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Emerging Growth

Relevium Technologies Inc.

Relevium Technologies Inc is engaged in the acquisition of products, technologies and businesses relating to musculoskeletal function, specifically Pain Relief, Injury Recovery and Active Performance.

Private Markets


Blockchain currencies (e.g. Bitcoin) provide a new disruptive way to transfer value between parties over the internet as opposed to going through banks. GoCoin provides online merchants with a suite…

Cross Campus

With over 500 members and operating 80,000 square feet by summer 2016, Cross Campus is one of the country’s top ten shared, collaborative office or "coworking" operators in the US.…